Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Lowers Price Target to $160

Benzinga · 1d ago
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and lowers the price target from $166 to $160.